CALIDI BIOTHERAPEUTICS INC

Calidi Biotherapeutics is a clinical-stage biotechnology company whose core therapeutic platform is dependent on animal testing. Its lead product candidates, including CLD-101 for treating solid tumors, are in preclinical and clinical development stages that require extensive animal research to evaluate safety and efficacy. This reliance on animal models is inherent to its business model and drug development pipeline.

The company's operations fall under the broad category of commercial animal exploitation, as its research activities involve the use of laboratory animals. While specific details of Calidi's internal animal welfare protocols are not publicly documented in the provided evidence, the company operates within a pharmaceutical research sector where animal testing is a standard, material component of bringing new therapies to market. The absence of a publicly available animal welfare policy or commitment to alternative testing methods further underscores its operational reliance on animal-based research.